摘要
目的 研究阿替普酶联合尤瑞克林救治急性脑梗死(ACI)患者的临床效果。方法 选取2019年5月至2022年6月漯河市第三人民医院神经内科收治的90例ACI患者作为研究对象,按随机数表法分为对照组和联合组各45例。对照组患者给予阿替普酶治疗,联合组患者在此基础上联合尤瑞克林治疗,两组患者均连续治疗14 d。比较两组患者治疗后的临床疗效,以及治疗前后的神经功能指标[美国国立卫生研究院卒中量表(NIHSS)评分]、氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]和血液流变学指标水平。结果 治疗后,联合组患者的治疗总有效率为93.33%,明显高于对照组的77.78%,差异有统计学意义(P<0.05);治疗后,联合组患者的NIHSS评分为(3.89±1.55)分,明显低于对照组的(5.86±1.81)分,差异有统计学意义(P<0.05);治疗前后,联合组患者的全血黏度、血浆黏度、血细胞比容水平、红细胞压积的差值分别为(6.57±1.04) m Pa·s、(3.65±0.35) mPa·s、(1.02±0.23)%、(16.40±1.91)%,明显高于对照组的(5.41±1.20) m Pa·s、(3.04±0.48) m Pa·s、(0.59±0.12)%、(13.93±1.99)%,差异均有统计学意义(P<0.05);治疗后,联合组患者的SOD、MDA水平分别为(177.18±22.35) U/mL、(5.60±1.25) nmol/mL,明显低于对照组的(238.86±21.41) U/mL、(8.91±2.33) nmol/mL,GSH-Px水平为(98.61±15.65) U/mL,明显高于对照组的(80.04±16.73) U/mL,差异均有统计学意义(P<0.05)。结论 阿替普酶联合尤瑞克林治疗能改善ACI患者氧化应激状态与血液流变学,提升治疗效果,且能进一步改善患者的神经功能。
Objective To study the clinical effect of ateplase combined with urinary kallidinogenase in the treatment of acute cerebral infarction(ACI).Methods A total of 90 patients with ACI who were admitted to the Depart-ment of Neurology at Luohe Third People's Hospital from May 2019 to June 2022 were selected as the research subjects.They were divided into a control group and a combination group by random number table method,with 45 patients in each group.Patients in the control group were treated with alteplase,while patients in the combination group were treat-ed with alteplase combined with urinary kallidinogenase.Both groups of patients were treated for 14 d.Clinical effects after treatment,neurological function[National Institutes of Health Stroke Scale(NIHSS)scores],oxidative stress indica-tors[superoxide dismutase(SOD),malondialdehyde(MDA),and glutathione peroxidase(GSH-Px)],and hemorheologi-cal indicators were compared between the two groups.Results After treatment,the total effective rate of treatment in the combination group was 93.33%,significantly higher than 77.78%in the control group(P<0.05).After treatment,the NIHSS score of the combination group was(3.89±1.55)points,significantly lower than(5.86±1.81)points of the control group(P<0.05).The difference values of whole blood viscosity,plasma viscosity,hematocrit,and hematokrit in the combi-nation group before and after treatment were(6.57±1.04)mPa·s,(3.65±0.35)mPa·s,(1.02±0.23)%,and(16.40±1.91)%,significantly higher than(5.41±1.20)mPa·s,(3.04±0.48)mPa·s,(0.59±0.12)%,and(13.93±1.99)%in the control group(P<0.05).After treatment,the levels of SOD and MDA in the combination group were(177.18±22.35)U/mL and(5.60±1.25)nmol/mL,significantly lower than(238.86±21.41)U/mL and(8.91±2.33)nmol/mL in the control group;the level of GSH-Px was(98.61±15.65)U/mL,significantly higher than(80.04±16.73)U/mL in the control group,with statistical-ly significant differences(P<0.05).Conclusion The combined treatment of ateplase and urinary kallidinogenase can improve oxidative stress,hemorheology,curative effect and neurological function in patients with ACI.
作者
王银浩
李惠敏
宋晓慧
WANG Yin-hao;LI Hui-min;SONG Xiao-hui(Department of Neurology,Luohe Third People's Hospital,Luohe 462000,Henan,CHINA)
出处
《海南医学》
2024年第2期190-193,共4页
Hainan Medical Journal
基金
河南省自然科学基金(编号:2022YX6235)。
关键词
急性脑梗死
阿替普酶
尤瑞克林
氧化应激
血液流变学
神经功能
Acute cerebral infarction
Ateplase
Urinary kallidinogenase
Oxidative stress
Hemorheology
Neu-rological function
